Skip to main content

Lupus

REstream Block (Upcoming)

        RT @RichardPAConway: Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white
        1 year 10 months ago
        Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF
        RT @JulianSegan: Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) f
        1 year 10 months ago
        Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful. @RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
        RT @uptoTate: DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and w
        1 year 10 months ago
        DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
        RT @Yuz6Yusof: #ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2
        1 year 10 months ago
        #ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
        RT @RichardPAConway: Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 y
        1 year 10 months ago
        Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI
        RT @ericdeinmd: Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
        Higher copays associated w/:
        💊39% lower odds of H
        1 year 10 months ago
        Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE Higher copays associated w/: 💊39% lower odds of HCQ adherence 💊56% lower AZA adherence 💊32% lower MMF adherence Need better $$ and transparency into costs. Screen for determinants of health affecting affordability! @Rheumnow https://t.co/1NdBb3GLzL
        RT @uptoTate: Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls.
        1 year 10 months ago
        Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
        RT @EBRheum: Excllent plenary, medication copay modifies treatment adherence in SLE

        >$10 copay reduced adherence fo
        1 year 10 months ago
        Excllent plenary, medication copay modifies treatment adherence in SLE >$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%) Easy to imagine that all our innovation cannot overcome access & barriers Should be priority to fix #ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy